BioKangtai and AstraZeneca sign a license termination agreement
I'm PortAI, I can summarize articles.
BioKangtai and AstraZeneca signed a termination agreement to end the research, production, and commercialization cooperation of the ChAdOx1 adenovirus vector COVID-19 vaccine. Due to changes in the market environment and the impact of COVID-19 vaccine variants, both parties decided to terminate the original licensing agreement after friendly consultations, with all rights and obligations ending from the effective date of the new agreement
Log in to access the full 0 words article for free
Due to copyright restrictions, please log in to view.
Thank you for supporting legitimate content.
Source: Zhitong The copyright of this article belongs to the original author/organization.
The views expressed herein are solely those of the author and do not reflect the stance of the platform. The content is intended for investment reference purposes only and shall not be considered as investment advice. Please contact us if you have any questions or suggestions regarding the content services provided by the platform.
Post your comment
No Comments